Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 89

1.

MR-spectroscopy guided target delineation for high-grade gliomas.

Pirzkall A, McKnight TR, Graves EE, Carol MP, Sneed PK, Wara WW, Nelson SJ, Verhey LJ, Larson DA.

Int J Radiat Oncol Biol Phys. 2001 Jul 15;50(4):915-28.

PMID:
11429219
2.

3D MRSI for resected high-grade gliomas before RT: tumor extent according to metabolic activity in relation to MRI.

Pirzkall A, Li X, Oh J, Chang S, Berger MS, Larson DA, Verhey LJ, Dillon WP, Nelson SJ.

Int J Radiat Oncol Biol Phys. 2004 May 1;59(1):126-37.

PMID:
15093908
3.

Metabolic imaging of low-grade gliomas with three-dimensional magnetic resonance spectroscopy.

Pirzkall A, Nelson SJ, McKnight TR, Takahashi MM, Li X, Graves EE, Verhey LJ, Wara WW, Larson DA, Sneed PK.

Int J Radiat Oncol Biol Phys. 2002 Aug 1;53(5):1254-64.

PMID:
12128127
4.

Longitudinal multivoxel MR spectroscopy study of pediatric diffuse brainstem gliomas treated with radiotherapy.

Laprie A, Pirzkall A, Haas-Kogan DA, Cha S, Banerjee A, Le TP, Lu Y, Nelson S, McKnight TR.

Int J Radiat Oncol Biol Phys. 2005 May 1;62(1):20-31.

PMID:
15850898
5.

Improved delineation of brain tumors: an automated method for segmentation based on pathologic changes of 1H-MRSI metabolites in gliomas.

Stadlbauer A, Moser E, Gruber S, Buslei R, Nimsky C, Fahlbusch R, Ganslandt O.

Neuroimage. 2004 Oct;23(2):454-61.

PMID:
15488395
6.

Potential value of MR spectroscopic imaging for the radiosurgical management of patients with recurrent high-grade gliomas.

Chuang CF, Chan AA, Larson D, Verhey LJ, McDermott M, Nelson SJ, Pirzkall A.

Technol Cancer Res Treat. 2007 Oct;6(5):375-82.

PMID:
17877425
7.

[Application of (1)H MR spectroscopic imaging in radiation oncology: choline as a marker for determining the relative probability of tumor progression after radiation of glial brain tumors].

Lichy MP, Bachert P, Hamprecht F, Weber MA, Debus J, Schulz-Ertner D, Schlemmer HP, Kauczor HU.

Rofo. 2006 Jun;178(6):627-33. Epub 2006 May 15. German.

PMID:
16703499
8.

Identification of MRI and 1H MRSI parameters that may predict survival for patients with malignant gliomas.

Li X, Jin H, Lu Y, Oh J, Chang S, Nelson SJ.

NMR Biomed. 2004 Feb;17(1):10-20.

PMID:
15011246
9.

L-(methyl-11C) methionine positron emission tomography for target delineation in resected high-grade gliomas before radiotherapy.

Grosu AL, Weber WA, Riedel E, Jeremic B, Nieder C, Franz M, Gumprecht H, Jaeger R, Schwaiger M, Molls M.

Int J Radiat Oncol Biol Phys. 2005 Sep 1;63(1):64-74.

PMID:
16111573
10.

Proton magnetic resonance spectroscopic imaging in newly diagnosed glioblastoma: predictive value for the site of postradiotherapy relapse in a prospective longitudinal study.

Laprie A, Catalaa I, Cassol E, McKnight TR, Berchery D, Marre D, Bachaud JM, Berry I, Moyal EC.

Int J Radiat Oncol Biol Phys. 2008 Mar 1;70(3):773-81. doi: 10.1016/j.ijrobp.2007.10.039.

PMID:
18262090
11.

Correlations between magnetic resonance spectroscopy and image-guided histopathology, with special attention to radiation necrosis.

Rock JP, Hearshen D, Scarpace L, Croteau D, Gutierrez J, Fisher JL, Rosenblum ML, Mikkelsen T.

Neurosurgery. 2002 Oct;51(4):912-9; discussion 919-20.

PMID:
12234397
12.

Malignancy assessment of brain tumours with magnetic resonance spectroscopy and dynamic susceptibility contrast MRI.

Fayed N, Dávila J, Medrano J, Olmos S.

Eur J Radiol. 2008 Sep;67(3):427-33. doi: 10.1016/j.ejrad.2008.02.039. Epub 2008 Apr 28.

PMID:
18442889
13.

Multiparametric 3T MR approach to the assessment of cerebral gliomas: tumor extent and malignancy.

Di Costanzo A, Scarabino T, Trojsi F, Giannatempo GM, Popolizio T, Catapano D, Bonavita S, Maggialetti N, Tosetti M, Salvolini U, d'Angelo VA, Tedeschi G.

Neuroradiology. 2006 Sep;48(9):622-31. Epub 2006 Jun 3.

PMID:
16752135
14.

[Metabolic imaging to follow stereotactic radiation of gliomas -- the role of 1H MR spectroscopy in comparison to FDG-PET and IMT-SPECT].

Lichy MP, Henze M, Plathow C, Bachert P, Kauczor HU, Schlemmer HP.

Rofo. 2004 Aug;176(8):1114-21. German.

PMID:
15346287
15.

[MR perfusion and spectroscopic imaging in WHO grade II astrocytomas].

Weber MA, Vogt-Schaden M, Bossert O, Giesel FL, Kauczor HU, Essig M.

Radiologe. 2007 Sep;47(9):812-8. German.

PMID:
16924439
16.

Proton magnetic resonance spectroscopic imaging integrated into image-guided surgery: correlation to standard magnetic resonance imaging and tumor cell density.

Ganslandt O, Stadlbauer A, Fahlbusch R, Kamada K, Buslei R, Blumcke I, Moser E, Nimsky C.

Neurosurgery. 2005 Apr;56(2 Suppl):291-8; discussion 291-8.

PMID:
15794826
17.

Combination of single-voxel proton MR spectroscopy and apparent diffusion coefficient calculation in the evaluation of common brain tumors.

Bulakbasi N, Kocaoglu M, Ors F, Tayfun C, Uçöz T.

AJNR Am J Neuroradiol. 2003 Feb;24(2):225-33.

18.

Magnetic resonance spectroscopic imaging-guided brachytherapy for localized prostate cancer.

DiBiase SJ, Hosseinzadeh K, Gullapalli RP, Jacobs SC, Naslund MJ, Sklar GN, Alexander RB, Yu C.

Int J Radiat Oncol Biol Phys. 2002 Feb 1;52(2):429-38. Erratum in: Int J Radiat Oncol Biol Phys. 2004 Nov 1;60(3):1011-2.

PMID:
11872289
19.

Variation of post-treatment H-MRSI choline intensity in pediatric gliomas.

Lazareff JA, Gupta RK, Alger J.

J Neurooncol. 1999 Feb;41(3):291-8.

PMID:
10359150
20.

Glioma grading: sensitivity, specificity, and predictive values of perfusion MR imaging and proton MR spectroscopic imaging compared with conventional MR imaging.

Law M, Yang S, Wang H, Babb JS, Johnson G, Cha S, Knopp EA, Zagzag D.

AJNR Am J Neuroradiol. 2003 Nov-Dec;24(10):1989-98.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk